Evidence map›Paper›PMID 34899095›Full record

ArticlePopulation, space and place2022

First wave of SARS-COV2 in Europe: Study and typology of the 15 worst affected European countries.

Alexandra Tragaki, Jean-Luc Richard

Abstract read
In one paragraph

Article in Population, space and place, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Occupation and SARS-CoV-2 in Europe: a review.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexandra TragakiDepartment of Geography Harokopio University Athens Greece.ORCID https://orcid.org/0000-0003-0768-3345
Jean-Luc RichardFaculté des Sciences Economiques Université de Rennes 1, UMR CNRS ARENES Rennes France.ORCID https://orcid.org/0000-0002-6723-4958

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 11 March 2020 when officially declared a global pandemic, Covid-19 (or SARS-COV2) has turned out to be a multifaceted disease differently affecting countries and individuals. What makes certain countries more vulnerable than others has attracted the interest of scientists from various disciplines. This paper intends to compare the impact of demographic parameters, population health conditions and policy actions on prevalence and fatality levels of Covid-19 during the first 3 months since its declaration of global pandemic. A country-level exploratory analysis has been conducted in order to assess how demography, national health conditions and measures taken interact and condition the disease outcomes. Analysis relies on publicly available data on Covid-19 reported cases, deaths and number of persons tested. Those data are combined with demographic parameters (sex ratio, mean age, population density and life expectancy), health data (cardiovascular death rate, diabetes prevalence, share of smokers among males and females and number of hospital beds) and information about relative national policies aiming the management of the pandemic (lockdown timing and duration). Our analysis confirms the diversity of factors and the complexity of their interaction in explaining the propagation and fatality of the disease across Europe. Our findings question some well-established attitudes concerning the role of demographic variables and public health conditions in the spread of the disease.

Indexed as

agecardiovascular death rateCovid‐19demographyEuropepandemicpolicy measuressex ratio

Identifiers

PMID34899095
PMCPMC8646875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.